Reaction profile

The FDA adverse-event record for pink eye

42 FDA reports name pink eye, a lower-volume reaction in the CVM extract (VeDDRA 2016). Plate stamps and neighbourhood peers follow.

#1834 of 2,481
by report volume (all reactions)
42
reports citing this reaction
28.6%
death-coded share
Cattle
most-affected species

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Pink eye has 42 reports now versus 42 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Pink eye changes

FDA AER · VeDDRA plate

Code 2016 VOL-TRACE

VOL-TRACE · DEATH-HOT · MID-PACK · PHOTO-FINISH · SPECIES-CATTLE · DRUG-LEAD · DESK-WIDE · BOOK-FULL

  • VOL-TRACE 42 reports
  • DEATH-HOT 28.6%
  • MID-PACK #1834/2481
  • PHOTO-FINISH Allergy to food
  • SPECIES-CATTLE Cattle · 24
  • DRUG-LEAD Milbemycin Oxime… · 10
  • DESK-WIDE 20 breeds
  • BOOK-FULL 8/8 fields

Nearest volume peer: Allergy to food (±0 reports)

Upper-third death-coded share drives the outcome stamps on this plate; volume band, corpus rank, and co-report peers follow. Not a clinical diagnosis.

Lower-volume neighbourhood around Pink eye

Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.

Vomiting · highest174348Allergy to food · near42Asystole · near42Cholecystitis · near42Cutaneous emphysema · near42Pink eye · this reaction42Urinary tract neoplas… · low…10
FDA AER report volume · neighbourhood around Pink eye

Pink eye: high death-coded share in the FDA AER plate

Signature read: 42 reports place Pink eye in the lower third of FDA AER volume (#1834 of 2,481). Report volume is lower-third scale: 42 named reports in the openFDA extract. Death-coded share is upper-third: 12 of 42 reports (28.6% of named reports). Nearest volume peer: Allergy to food (±0 reports). Lead species Cattle (24). Lead co-reported drug Milbemycin Oxime + Spinosad (10).

Read these counts as reporting volume, not risk: per our methodology, A high death-coded share in FDA filings does not prove causation; co-reporting is voluntary temporal association only. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Cattle 24
Dog 14
Cat 3
Human 1

Breeds Most Affected

Cattle (other) 7
Cattle (unknown) 5
Crossbred Bovine/Cattle 5
Mixed (Cattle) 4
Boxer (German Boxer) 2
Mixed (Dog) 1
Maltese 1
Retriever - Golden 1
Doberman Pinscher 1
Siberian Husky 1

Associated Drugs

Milbemycin Oxime + Spinosad 10
Monensin Sodium 6
Moxidectin 5
Trenbolone Acet/Estradiol Impl 3
Tylosin Phosphate 3
Clostridium Chauvoei-Septicum-Novyi-Sordellii-Perfringens Types C And D-Moraxella Bovis Bacterin-Toxoid 2
Zeranol Implant 2
Pirimiph/Lambda-Cyhalot Eartag 2
Rabies Vaccine 2
Fenbendazol Suspension 2
Clostr Perf*2/Clos Others*4 Kb 2
Bovine Virus*5/Past M+Mh Lv/Lb 2
Moraxella Bovis Bacterin 2
Narasin 2
Tilmicosin 2
Mannheimia Haemolytica Bacterial Extract-Toxoid 2
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3-Respiratory Syncytial Virus Vaccine 2
Clostridium Chauvoei + Septicum + Haemolyticum + Novyi + Tetani + Perfringens Types C & D Bacterin-Toxoid 2
Selamectin;Sarolaner 2
Lotilaner 2

What to do with this reaction

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Pink eye (#1834 of 2,481 by report volume); death-coded 28.6%. PlainBreed reaction plate · report volume stamp 42 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →